 The National Pharmaceutical Pricing Authority (NPPA) has formally intervened in the escalating conflict between traditional brick-and-mortar chemists and digital drug platforms by responding to a major complaint filed by the Tamil Nadu Chemists and Druggists Association (TNCDA).
In a detailed communication dated February 23, 2026, the NPPA clarified the regulatory boundaries (legal limits) governing medicine costs in India while addressing the association’s concerns over online price variations. This response marks a significant milestone for the TNCDA, which has spent the last one year engaged in an all-out war against the rise of online pharmacies, citing threats to both public health and fair trade.
In its official response, the NPPA outlined the strict mechanisms of the Drugs (Prices Control) Order (DPCO), 2013, noting that it regularly fixes and revises ceiling prices for scheduled formulations based on the Wholesale Price Index (WPI). For non-scheduled drugs, the regulator reminded stakeholders that while manufacturers have the liberty to set initial prices, they are legally prohibited from increasing the Maximum Retail Price (MRP) by more than 10 percent within a single year. However, the NPPA notably clarified that the heavy discounts offered by web portals, a primary grievance of the TNCDA, currently fall outside its specific price-fixing purview.
Perhaps the most critical development for the association is the NPPA’s decision to elevate allegations of spurious drugs to the highest level of drug enforcement in the country. The NPPA has sent a formal referral letter to the Drugs Controller General of India (DCGI) at the Central Drugs Standard Control Organization (CDSCO) to investigate reports that branded medicines from well-known companies are being illegally manufactured and sold under false names through online platforms. This referral emphasizes that such practices could lead to dangerous, counterfeit medications entering the market, a matter that requires the urgent necessary action of the DCGI.
The TNCDA’s persistence over the past one year has been characterized by a massive outreach campaign that extends far beyond local borders. Driven by fears of predatory pricing and unregulated distribution, the association has drafted a series of high-profile appeals to the Prime Minister, the Union health minister, and the state chief minister. Their crusade even took an international turn with a letter sent to the President of the United States, highlighting the global implications of the international online pharmacy business and the potential for cross-border pharmaceutical misconduct.
For the chemist community of Tamil Nadu, the NPPA’s referral to the DCGI serves as a partial validation of their long-standing claims that online portals operate with insufficient oversight. The association has argued that the convenience of digital storefronts should not come at the cost of patient safety or the economic stability of local pharmacies.
The NPPA has also encouraged the TNCDA and the general public to utilize digital tools like the ‘Pharma Sahi Daam’ app and the ‘Pharma Jan Samadhan’ portal to report any further instances of overcharging or DPCO violations. This move suggests that while the regulator may not control the discounts offered by e-pharmacies, it remains committed to ensuring that no entity, online or offline, exceeds the government-mandated price ceilings. The emphasis on providing proper invoices and batch details in these complaints underscores a push for greater transparency in the pharmaceutical sector.
As the DCGI begins its review of the referred complaint, the TNCDA shows no signs of retreating from its year-long campaign. The outcome of this investigation could set a major precedent for how online pharmacies are regulated in India, potentially leading to stricter enforcement of the Drugs and Cosmetics Act.
|